Commissioner Scott Gottlieb is hoping the US FDA can help grow biomarker development in the same way it fostered modeling and simulation practices.
To make that happen, a new Office of Drug Development Science is expected to be added as part of the reorganization and modernization of the Office of New Drugs. Gottlieb said in a talk to the J.P
The office's goal will be to "try to bring much more consistency and rigor around certain elements of drug development science that we think now are hard sciences and are more